A central epidemiological feature of cancers of the breast, endometrium and ovary is the sharp slowing down in their rate of increase with age around the time of menopause. The incidence of these tumors by the age of 70 years would be between fourfold and eightfold increased if the rapid increase with age seen in young women continued into old age. These phenomena can be explained by the different effects of ovarian hormones on cell division rates in the relevant tissues. Models of these effects provide a plausible explanation of most of the known epidemiology of each of the cancers, including the increase in breast cancer risk from menopausal estrogen-progestin therapy. Some recent epidemiological findings in endometrial and ovarian cancer suggest new avenues for possible chemoprevention of these cancers.
Introduction
An accelerating increase in incidence with increasing age is a striking feature of most adult cancers. The relationship between incidence, I(t), and age, t, for these cancers follows quite closely a simple power relationship:
where a is a constant and k is usually between 4 and 5. For these cancers, a plot of the logarithm of incidence against the logarithm of age produces a straight line of slope 4 or 5. Figure 1 shows this relationship for colorectal cancer (Cutler and Young, 1975) . This almost exponential increase in cancer incidence with increasing age can be attributed to a multistep carcinogenic progression in which the underlying processes, including mutation, proliferation and regression of intermediate precancerous lesions, proceed at a constant rate throughout adult life (Doll, 1971; Peto, 1977) .
Whatever the reason for the form of the equation, deviations from this form are easily recognized and provide fundamental insights into risk factors for the deviant cancer. Figure 2 (Cutler and Young, 1975) shows the age-specific incidence rates for breast cancer in US white females in 1969-1971 before mammographic screening and widespread use of menopausal estrogen-progestin therapy (EPT) had distorted the picture. In contrast to the curve shown in Figure 1 , there is an abrupt slowing down of the rate of increase in incidence around the age of 50 years. The age-specific incidence curves for endometrial and ovarian cancer ( Figures 3 and 4) show a similar slowing down of the rate of increase around the same age. These incidence curves can be made to fit into the form of Equation (1) by expressing the equation in a more general form:
where d(t) is the 'effective tissue age' of the relevant tissue up to age t. At a given age, the rate of 'tissue ageing' is the rate at which underlying carcinogenic processes such as mutation, proliferation and cell death take place. We assume that it is roughly equal to mitotic rate, or perhaps cell death and resulting replacement (Cairns, 2002) , in some stem cell compartment. For lung cancer, the 'effective tissue age' is almost exactly duration of smoking up to age t, as both early and late stages in lung carcinogenesis are strongly affected by tobacco (Doll, 1971) . For hormone-dependent tissues 'effective tissue age' probably represents at least approximately the cumulative number of stem cell divisions up to age t. The hypothesis is simply that hormones affect cancer incidence mainly through their effect on mitotic rates in the stem cell compartment, both by increasing the probability of a DNA-damaging event becoming fixed as a mutation (Dao, 1981) and through their promoting effect seen in certain animal experimental systems (Welsch, 1981) . This can be expressed mathematically through the 'effective tissue age ' (d(t) in Equation (2)) to give models that account for many of the known risk factors of hormonedependent cancers (Henderson et al., 1982) .
In these terms, Figures 2-4 show that for each of these cancer sites the rate of increase of 'effective tissue age' decreases around the age of 50 years. This change in slope of the age-specific incidence curves at this age strongly suggests an effect of menopause. By reducing mitosis, menopause slows the rates of both spontaneous and environmentally induced mutations in the relevant stem cells. Therefore, early menopause will have a protective effect on each of these cancers. If ceasing ovulation reduces risk, early age at menarche should increase it. The simplest mitotic rate model for these cancers must thus have a sharp increase in the rate of 'effective tissue ageing' at menarche and a fairly steep fall at menopause.
In this paper, we will discuss cancers of the breast, endometrium and ovary in terms of this model. The model was fitted by setting f, the rate of 'tissue ageing' at each period in a woman's reproductive life, at a different constant level. This rate is cumulated to give the 'effective tissue age ', d(t) , at age t. Thus, for breast cancer, the fitted rate ( Figure 5 ) was f 1 ¼ 1 from menarche to first birth, f 2 ¼ 0.7 from first birth to menopause, and f 3 ¼ 0.1 after menopause. We will draw attention to defects in the fit of these models and how these defects point us to the direction further research should take, keeping in mind that the main purpose of epidemiological research on these tumors is to guide us in finding ways to prevent them.
As we have noted, Figures 2-4 suggest that breast, endometrial and ovarian cancer are driven by some aspect of ovarian function. Oophorectomy will significantly reduce the incidence of all three cancers. This is, however, not an acceptable intervention except for women at very high risk of the diseases. The problem is to find out precisely what aspect of ovarian function is responsible for increasing risk, possibly different for the three cancers, so that an acceptable and effective prevention approach can be developed. Figure 1 Age-specific incidence rates for colorectal cancer in US white women, 1969 -1971 (Cutler and Young, 1975 Age ( Figure 2 Age-specific incidence rates for breast cancer in US white women, 1969 -1971 (Cutler and Young, 1975 Age ( , 1968 , -1972 , (Waterhouse et al., 1976 Age ( , 1968 , -1972 , (Waterhouse et al., 1976 We are concerned here in particular with finding chemoprevention approaches to prevention. That significant chemoprevention is possible for endometrial and ovarian cancer is known since oral contraceptives (OCs) provide it, but they do not provide protection against breast cancer.
Cancer of the breast
The three major reproductive risk factors for breast cancer are late menopause, early menarche and late first full-term pregnancy (FFTP; Kelsey and Bernstein, 1996; Colditz and Rosner, 2000) . Women whose natural menopause occurs before the age of 45 years have only about one-half the breast cancer risk of those whose menopause occurs after the age of 55 years. The increased breast cancer risk among women with earlier menarche is most noticeable at premenopausal ages. With regard to late FFTP, women with a FFTP under the age of 20 years have about one-half the risk of nulliparous women, but nulliparous women do not have as high a risk as women whose FFTP is after about the age of 32 years.
A definition of the rate of 'tissue ageing' with increasing age that accounts in quantitative terms for these three risk factors and the age-incidence curve shown in Figure 2 was given in Pike et al. (1983) . This definition, shown in Figure 5 , assumes that breast 'tissue ageing' starts at menarche at a constant rate up to FFTP, then continues at a reduced rate until the start of the perimenopausal period (around the age of 40 years), declining gradually thereafter to a low postmenopausal rate. To account for FFTP after around the age of 32 years being associated with a breast cancer rate that is larger than that of nulliparous women, the model includes an abrupt but transient increase in 'tissue ageing' during the pregnancy. With this simple definition of the rate of 'tissue ageing', the effects of menopause, menarche, and FFTP are well mimicked with the following rates. Taking the rate of breast 'tissue ageing' from menarche to FFTP as 100%, the rate increases to about 400% during FFTP, then falls to 70% until menopause, and to 10% thereafter. The fitted exponent of time (k) was 4.5, similar to the best-fitting value for many epithelial cancers . The fit of the model is shown by the smooth curve in Figure 2 . This model has been extended by Rosner et al. (1994) to include a transient increase during each later pregnancy, and other risk factors can be incorporated in the same way (Colditz and Rosner, 2000) . However, the basic model shown in Figure 5 suffices to explain the underlying concept and its implications for chemoprevention.
Age at FFTP
This model predicts that at young ages nulliparous women as a group will have lower breast cancer rates than parous women as a group. This initially surprising conclusion is supported by breast cancer incidence and mortality data at young ages (Office of Population Censuses and Surveys, 1978) , which show that breast cancer rates of married women are substantially greater than those of single women before the age of 25 years and exceed the rates of married women only after the age of 35 years. When these observations were first made by Janerich (1979) , there was a great deal of argument about their validity and interpretation. We now know that births, and particularly FFTP, are followed by a transient increase in incidence. Pike et al. (1983) showed how this can explain the 'anomaly' of women with a late age at FFTP having a higher breast cancer risk than nulliparous women; the benefit of FFTP in reducing the subsequent breast 'tissue aging' rate does not have long enough (before the postmenopausal drop in rate occurs) to compensate for, and then more than compensate for (if the FFTP occurred early enough) the increased rate during the pregnancy.
Breast cell mitotic rate during the menstrual cycle
Understanding the relationship of breast cell mitotic activity to the phase of the menstrual cycle was essential to relating this model of breast cancer risk to the biology of the breast. This information was forthcoming in the early 1980s in a series of studies, which showed that mitotic activity of breast epithelium varies markedly during the normal menstrual cycle, with peak activity occurring in the luteal phase ( Figure 6 ; Anderson et al., 1982; Pike et al., 1993) . This shows that regular (ovulatory) cycling is positively correlated with mitotic activity and explains why delay in establishment of regular cycles after menarche will decrease breast cancer risk ). The pattern is quite different in the endometrium, in which mitotic activity is effectively confined to the follicular phase.
Low breast cancer rates in Japan
As of 1970, age-adjusted breast cancer rates were some five to six times higher in the US than in Japan, although the Japanese rate has increased substantially since then. This difference was and remains of great interest to epidemiologists. It cannot be due to differences in Pike et al., 1983) genetic susceptibility, as the rate in Japanese-Americans in Hawaii is now similar to the rate in white women . We used the above model to evaluate the role of ages at menarche, first birth and menopause in producing these differences in risk . Older Japanese women had a much later menarche than American women and this would significantly reduce their risk; but the data on first birth, nulliparity, and menopause showed that none of the decreased breast cancer rates in Japan could be attributed to these factors.
Japanese breast cancer rates remained almost constant after the age of 50 years (Fujimoto et al., 1979) . In model terms, this implies that 'tissue ageing' ceases at menopause in Japanese women. The latter effect could be explained by their much lower postmenopausal estrogen levels due to their weight being much lower than that of US women. Although the rates predicted for older Japanese women based on their later age at menarche and with a zero postmenopausal 'tissue ageing' rate (f 2 ) are considerably lower than the observed rates for US white women, they were still more than 2.5-fold greater than the observed Japanese rates. The difference was already evident at premenopausal ages and this suggested that lower levels of premenopausal estrogen and progesterone might be seen in 'traditional' Asian women. This was confirmed in studies conducted during the mid-to late 1980s (Goldin et al., 1986; Bernstein et al., 1990; Key et al., 1990; Shimizu et al., 1990) . The reduced levels of serum estrogens and probably progesterone seen in 'traditional' Asian premenopausal women provides a plausible explanation of the remainder of the large difference in risk between traditional Japanese and US women.
OCs
Many epidemiological studies have been conducted to evaluate the effect of OC use on breast cancer risk. The main result of these studies as regards our fundamental understanding of breast cancer etiology is that, whatever effect there is, it is small. This suggests that the total breast cell proliferation of women on OCs should be very close to that seen during normal menstrual cycles, and that is precisely what is seen .
Obesity
The overall effect of obesity is to increase the risk of breast cancer, but this increased risk is restricted to older postmenopausal women (Kelsey and Bernstein, 1996) . In premenopausal women, obesity is associated with a reduction in risk. These effects are predicted by their estrogen-progesterone milieu. Premenopausal obesity is associated with increased anovulation with decreased serum hormone levels of both estrogen and, especially, progesterone. Postmenopausal obesity is associated with increased serum estrogen levels, so that the decreased risk associated with premenopausal obesity is gradually eliminated and an increased risk finally attained. There is, however, accumulating evidence that breast tissue levels of estrogen may be uncorrelated with serum estrogen levels (Blankenstein et al., 1999) . This suggests that the above explanation may be fundamentally flawed; more work is needed to clarify this issue.
Mammographic densities
The extent of mammographic densities (i.e., the white areas in a standard mammogram of the breast representing connective and epithelial tissue) are correlated with breast cancer risk, and the variation in risk is greater than that seen with almost all other breast cancer risk factors (Table 1) . For technical reasons, in particular to enable the use of mammograms taken on different machines and by different operators, mammographic densities are not usually measured as an absolute amount but as a percent of the breast area on the mammogram, the mammographic percent density (MPD) ( Figure 7 ).
As can be seen from Table 1 , MPD varies enormously between different women. This variability has a strong genetic component (Boyd et al., 2002) and is also partly under hormonal control (Spicer et al., 1994; Greendale et al., 2003) . Bilateral oophorectomy with add-back menopausal estrogen therapy (ET) causes a decrease of approximately 10% in MPD (Gram et al., 2001) , and, extrapolating from the results of a study of the effect of menopausal hormone therapy on MPD (Greendale et al., 2003) , this appears to be almost independent of the initial level of MPD. In a randomized study, Breast, endometrial and ovarian cancer prevention MC Pike et al Greendale et al. (2003) found a 1.2% increase in MPD with ET and a 4.6% increase with the EPT of the Women's Health Initiative (WHI) trial (Chlebowski et al., 2003) . MPD is thus a measure of ovarian hormone exposure, but only a small amount of variability in MPD is accounted for by differences in hormone exposure. However, change in MPD is closely associated with change in hormone exposure (Gram et al., 2001 ).
Menopausal hormone therapy
Epidemiological studies have estimated that menopausal estrogen therapy (ET) causes an approximately 10% increase in breast cancer risk after 5 years of use, that is, a 10% increase in risk at the 5-year point after 5 years of use or a cumulative increase in risk for 5 years of use of approximately half this amount (Collaborative Group on Hormonal Factors in Breast Cancer, 1997) , and the WHI trial of ET in hysterectomized women found no increase in risk (Anderson et al., 2004) . Epidemiological studies of menopausal EPT found a considerably greater risk in the range of 25-40% (Magnusson et al., 1999; Colditz and Rosner, 2000; Ross et al., 2000; Schairer et al., 2000) . This very significant risk associated with EPT was confirmed by the WHI randomized trial of the effects of the most commonly prescribed EPT regimen, namely continuous combined EPT with conjugated equine estrogens (CEE) at 0.625 mg/day and medroxyprogesterone acetate (MPA) at 2.5 mg/day. The WHI result was a cumulative 26% increase in risk for approximately 5.2 years of use (Chlebowski et al., 2003) ; this is equivalent to an approximately 50% increase at 5 years of use.
The effects on breast cancer incidence of oophorectomy (a reduction of B60%) or 5 years of EPT (an increase of about 40%) are thus roughly proportional to the changes observed in MPD with these treatments (a decrease of 10% following oophorectomy, and an increase of 4.6% for EPT).
Chemoprevention with 'antihormonal' drugs
Chemoprevention of breast cancer in postmenopausal women by the selective estrogen receptor modulator (SERM) tamoxifen has been clearly established (Lippman and Brown, 1999) , and there is good evidence that another SERM, raloxifene, may be equally or even more effective (Cauley et al., 2001) . Furthermore, there is good evidence that the modern aromatase inhibitors are more effective in the treatment of breast cancer than tamoxifen and that they will be as good or better than tamoxifen as chemoprevention agents. The main issues that need to be resolved with the use of these agents relates to important side effects associated with their use. We can confidently predict that steady progress will be made in improving this 'antiestrogen' approach to postmenopausal chemoprevention.
The dose of estrogen and progestin in OCs, including current low dose OCs, must be sufficient to block ovulation and provide a satisfactory control of spotting. We have suggested (Pike et al., 1989; Spicer et al., 1991) that chemoprevention of breast cancer in young premenopausal women could be achieved by a contraception approach in which ovulation is inhibited by the use of a gonadotropin releasing hormone analog (GnRHA). Use of a GnRHA to block ovulation permits the add-back dose of estrogen and progestin to be selected purely on the basis of providing protection from the hypoestrogenism induced by blocking ovulation and the need to protect the endometrium; we suggested that a dose of estrogen equivalent to that used in ET with very intermittent progestin (10-12 days every 4 months) would provide such protection. This approach has been demonstrated to be acceptable to women at high risk of breast cancer with minimal bone loss and significant reductions in mammographic density (Spicer et al., 1994; Ursin et al., 1998; Gram et al., 2001) . Similar reductions in mammographic density were subsequently seen in a small number of women with BRCA1 mutations. As we have noted, total breast cell mitotic activity is very similar in OC cycles and natural ovulatory cycles, whereas the reduction in mammographic density induced by the GnRHA suggests that breast cell proliferation has been significantly reduced. Further clinical development is needed, but the potential reduction in breast cancer risk from such an approach is of the same order of magnitude as the reductions in both endometrial and ovarian cancer in OC users (see below).
Chemoprevention by mimicking early first birth
The 'mechanism' by which an early first birth protects against breast cancer is poorly understood. In the rat, Russo et al. (1991) showed that a term pregnancy induced Boyd et al. (1995) . permanent differentiation of terminal end buds and a substantial reduction in breast cancer induced by 7,12-dimethylbenzanthracene (DMBA). Russo and Russo (1994) also reported that these same pregnancy-induced breast changes and reduced breast cancer risk could be affected by treating the rats with the placental hormone chorionic gonadotropin, and proposed that treating young women with human chorionic gonadotropin (hCG) would similarly significantly reduce their risk.
Evidence that such differentiation of the breast occurs in women with a term pregnancy is weak, but Bernstein et al. (1995) found in a breast cancer case-control study of young women in Los Angeles that hCG treatment was associated with an approximately 40% reduced risk of breast cancer in nulliparous women. This intriguing observation was associated with a wide confidence interval but it needs to be further pursued. The women had had hCG injections as part of a now not-practiced weight reduction program (Simeons, 1954) and was not sufficiently common for it to be effectively pursued by standard epidemiological case-control methods. Looking for associated reductions in mammographic densities with use of hCG in nulliparous women as are seen in parous compared to nulliparous women may be rewarding (El-Bastawissi et al., 2001; Jakes et al., 2002; Gapstur et al., 2003) .
Cancer of the endometrium US age-specific incidence data for both endometrial and ovarian cancer are difficult to interpret because the very high rate of hysterectomies and oophorectomies in the US means that the denominator for calculating rates cannot be accurately estimated. Data from the UK around 1970 suffer much less from this problem and we use such data to illustrate the situation for cancer at these two sites. Data from around 1970 also avoid the distortion of the endometrial cancer rates from the widespread use of OCs, which decreases risk, and menopausal ET, which increases risk, and the distortion of the ovarian cancer rates from widespread use of OCs, which decreases risk. Figure 3 shows the age-specific incidence curve for endometrial cancer in women in the Birmingham region of the UK, 1968 -1972 (Waterhouse et al., 1976 . The suggestion of a strong protective effect of menopause is again evident.
The major reproductive risk factors increasing endometrial cancer risk are late menopause and early menarche, while increasing parity decreases risk (Key and Pike, 1988) . OC use decreases risk significantly, while risk is greatly increased in obese women. All these results can be explained by the 'unopposed estrogen' hypothesis for endometrial cancer that risk is increased by exposure of the endometrium to estrogen unopposed by progesterone or a synthetic progestin.
A definition of the rate of increase in endometrial 'tissue age' with increasing age that describes in quantitative terms the effect of menopause, menarche and parity on the age-incidence curve shown in Figure 3 was given in Pike (1987) . This definition considers endometrial 'tissue age' as moving at rate of f 0 ( ¼ 1) during normal menstrual cycles and at rate f 1 (o1) during pregnancies and during the postmenopausal period. With this definition, the effects of menopause, menarche and parity are well mimicked with the following parameters: f 1 ¼ 0.15 and k ¼ 6 (Pike, 1987) . The fit of the model is shown by the smooth curve in Figure 3 .
The model predicts that each birth will have the same quantitative effect on reducing risk; although this was seen in a number of studies, in general first birth has a greater effect than subsequent births. There is also evidence that a late age at last birth may be associated with a further reduction in risk independent of parity. OC use for 1 year is considerably less protective than a single birth even a birth after the first.
Endometrial cell mitotic rate during the menstrual cycle
The relationship of endometrial cell mitotic activity to the phase of the menstrual cycle is critical in understanding the etiology of endometrial cancer. Endometrial cell proliferation is exquisitely sensitive to the effects of estrogens 'unopposed' by progestin (see Key and Pike (1988) for comprehensive list of references). Although there are some gaps in the data, endometrial cell proliferation appears to be close to maximal for some 18 days of the menstrual cycle covering the follicular and early luteal phase of the cycle, with close to no endometrial cell proliferation for the last 10 days of the cycle.
Parity
As we noted above, there is a greater reduction in risk with first birth than with subsequent births (Pettersson et al., 1986; Kvale et al., 1988; Brinton et al., 1992; Albrektsen et al., 1995; Lambe et al., 1999) : an approximately 30% reduction in risk with first birth compared to an approximately 15% reduction with each subsequent birth.
In their cohort study, Kvale et al. (1988) found that a late age at last birth was associated with a significant reduction in risk independent of parity. This effect has now been found in a number of studies (Albrektsen et al., 1995; Lambe et al., 1999) , although the effect is not always seen (Pettersson et al., 1986; McPherson et al., 1996) . In our study , we found that compared to a nulliparous woman, risk of endometrial cancer was reduced by 51% in a woman with a last birth after the age of 35 years and that additional births (before the last) reduced risk further by an average of an additional 15% per birth. A last birth before the age of 25 years was associated with only a 12% reduced risk of endometrial cancer.
Our results on the effects of age at last birth are in good agreement with the results seen in the three other positive studies although the differential effect was not quite so large in the study of Lambe et al. (1999) . In the study of McPherson et al. (1996) , 'older age at last pregnancy appeared protective until controlled for gravidity', but the authors did not give the adjusted (controlled) results. The effect of age at last birth should probably be considered as requiring further supportive data before it can be assumed as firmly established.
OC use
OC use is associated with a significant reduction in endometrial cancer risk. At premenopausal ages, the risk is reduced by approximately 10% per year of use Cancer and Steroid Hormone Study, 1987a) , but this declines with increasing age. OCs are a mixture of estrogen (almost solely ethenyl-estradiol) and a progestin. Their composition is such that they are progestin dominant for the endometrium, so that endometrial proliferation is confined effectively to the days on which the OC is not taken. On the assumption that endometrial proliferation will be proportional to the number of days of unopposed estrogen the reduction in risk with OC use is calculated to be about 10%; this is calculated by comparing the 18 days of proliferation during a normal menstrual cycle to the 7 days on an OC and then calculating the ratio of the total cell proliferation to the age of 50 years in an 'average' woman who does and does not use an OC for a year, finally raising the resulting ratio to the power 6. We note that this form of calculation suggests that a birth should be associated with a 16% reduction in risk; close to that found to be associated with births.
Obesity
Obesity is associated with a greatly increased risk of endometrial cancer. This is evident both at premenopausal Cancer and Steroid Hormone Study, 1987a ) and postmenopausal ages (Pike et al., 1997) . At premenopausal ages, it results from the associated anovular cycles in which the endometrium is stimulated throughout the cycle, and this is then made worse during the postmenopausal period when the obesity is associated with both higher levels of estrogen from extraglandular conversion of androgens to estrogens and lower levels of sex-hormone-binding globulin so that the estrogen produced is more bioactive (Siiteri and MacDonald, 1973; Siiteri et al., 1981) .
Menopausal hormone therapy
Menopausal ET substantially increases a woman's risk of developing endometrial cancer. To reduce this increased cancer risk, progestins were added to ET, menopausal EPT, for between 5 and 15 days (usually 7 or 10 days) per month in a sequential manner (sequential EPT). Sequential EPT causes regular bleeding in many women and is associated with other negative side effects, so that subsequently, continuous combined therapy regimens were developed in which estrogen and a lower dose of progestin are always taken together (continuous combined EPT). Continuous combined EPT is not associated with regular bleeding, but there is significant spotting.
With the dose of ET most commonly used in the US, that is, conjugated equine estrogens (CEE) at 0.625 mg/ day, we found that endometrial cancer risk is increased approximately 120% at 5 years of use (Pike et al., 1997) . For women who received sequential EPT with the progestin medroxyprogesterone acetate (MPA) at 5 or 10 mg/day given for around 7 days per month, endometrial cancer risk was still markedly elevated with an estimated increase of 87% at 5 years of use. However, quite remarkably, when progestin was given for 10 or more days the increased risk was estimated to be only 10% at 5 years of use and this result was not statistically significant from no increase in risk. Continuous combined EPT was associated with essentially no increased risk.
CEE at 0.625 mg/day, unopposed by a progestin, results in endometrial cell proliferation approximating that found during the follicular phase of the menstrual cycle (King and Whitehead, 1984) , and this can be completely blocked by MPA at 5 or more mg/day (Lane et al., 1986) . This abolition of cell proliferation and the observation that 'Seveny[is the]y number of days that the level of progesterone is above 5 ng/mL in the normal menstrual cycle ' (Flowers et al., 1983) , persuaded many prescribers that 7 days of progestin was sufficient to abolish any risk. However, progestin use for 7 days did not completely remove the risk of hyperplasia (Paterson et al., 1980) , and 10 or more days of progestin therapy became standard practice (King and Whitehead, 1984) . It should be pointed out that, as can be seen in Figure 3 , endometrial cancer incidence is increasing rapidly in the premenopausal period, even where obesity is uncommon, so that the notion that mimicking the progestin phase of the menstrual cycle would provide adequate protection was always suspect. Key and Pike (1988) had previously argued that, if endometrial cell proliferation in the basalis (stem-cell) layer was the key to increased risk from ET, there would still be an increased risk from sequential EPT even with 10 days of progestin use, since there would still be unopposed estrogen for around 15 days per treatment cycle (sequential EPT was usually given for 25 days per 28-day cycle). This prediction was clearly contradicted by the epidemiological results showing that endometrial cancer risk was almost eliminated with 10 days of progestin use. A simple cell proliferation model for endometrial cancer is not tenable.
In their studies of endometrial tissue after 7 days of progestin therapy, Flowers et al. (1983) found that such short progestin use did 'not cause all the endometrium to desquamate to the basalis layer [only] 40 to 50% of the functional layer. was lost'. If these functionalis cells are susceptible to cancer, and if a much greater proportion of such cells are lost with longer progestin therapy, this could provide an explanation for the sharp distinction between 7 and 10 days use. It would also be consistent with the observation of pathologists that early stage tumors often appear to arise in the functionalis. This could also provide an explanation for the great protective effect of a late age at last birth.
Such endometrial sloughing may also provide an explanation for the observations made some 10 years ago that CEE at 0.625 mg/day did not produce hyperplasia if 10 mg of MPA was given for 14 days every 3 months (Ettinger et al., 1994; Williams et al., 1994) . Hyperplasia did occur in a further trial in which estradiol was given at 2 mg/day for 68 days, followed by norethisterone at 1 mg/day for 10 days and finally estradiol at 1 mg/day for 6 days (Cerin et al., 1996) . This may simply be a dose of estrogen effect and would provide a further reason for the steady large increase in premenopausal endometrial cancer with age.
Chemoprevention
OC use remains an effective approach to chemoprevention of endometrial cancer: in our data and in recently published studies, the protective effect was seen to be very long term.
If the finding of a major protective effect of a late birth can be confirmed, then we may be able to use this for a short-duration chemoprevention strategy with a long-term preventive effect. To do this, we will need to understand the mechanism of the protective effect. Further detailed study of the endometrium at or soon after delivery, and comparisons with the endometrium in women on OCs and during regular cycling would hopefully lead to a deeper understanding of the origin and possible prevention of endometrial cancer. Figure 4 shows the age-specific incidence curve for invasive epithelial ovarian cancer (ovarian cancer) in women in the Birmingham region of the UK, 1968 -1972 (Waterhouse et al., 1976 . The suggestion of a strong protective effect of menopause is again evident. A number of epidemiological studies have found this suggested protective effect of early menopause, but this effect has not been seen as consistently as it has been found for breast and endometrial cancer.
Cancer of the ovary
Epidemiological studies have consistently found that the risk of ovarian cancer is significantly decreased with increasing numbers of births, and Fathalla (1972) proposed that the mechanism of this effect was the interruption of the tearing of the ovarian surface epithelium (OSE) with each ovulation (the 'incessant ovulation hypothesis'). OSE (on the surface or trapped in inclusion cysts) is regarded by most pathologists, although not by all (Dubeau, 1999) , as the tissue of origin of ovarian cancer, and it was the increased cell division of the OSE involved in the repair of the surface after each ovulation that was considered to be the major factor increasing ovarian cancer risk. The epidemiological findings of a significant protective effect of OC use (Newhouse et al., 1977; Casagrande et al., 1979; Cancer and Steroid Hormone Study, 1987b) provided further support for this hypothesis.
A definition of the rate of increase in ovarian 'tissue age' with increasing age that describes in quantitative terms the suggested effect of menopause and the wellestablished protective effect of parity on risk, as well as the age-incidence curve shown in Figure 4 , was given in Pike (1987) . This definition considers ovarian tissue (i.e., the tissue that gives rise to ovarian cancer) exposure as moving at rate of f 0 ( ¼ 1) during normal menstrual cycles and at rate f 1 (o1) during pregnancies and during the postmenopausal period. With this definition, the effect of parity and the age-incidence curve are well described with f 1 ¼ 0.09 and k ¼ 4. The fit of the model is shown by the smooth curve in Figure 4 .
The model predicts that each birth will have the same quantitative effect on reducing risk. This is not seen in epidemiological studies; first birth provides considerably more protection than subsequent births; that is, nulliparous women are at especially high risk. This is partly due to the inclusion in the nulliparous group of women who were infertile and there is now evidence that they are at especially high risk. However, this only explains part of the considerable excess risk of nulliparous women. It now also appears that age at last term pregnancy has a major effect on risk and that understanding the etiology of ovarian cancer needs to take this into account. The model also predicts that approximately 1 year of OC use would be as protective against ovarian cancer as a fullterm pregnancy. Epidemiological data are in line with this if one considers the protection from full-term pregnancies after the first.
'Ovarian cell' mitotic rate during the menstrual cycle
There have been no studies of the mitotic rate of OSE (either on the surface or in inclusion cysts) during the menstrual cycle, other than the obvious repair of the surface OSE that occurs after each ovulation. It is also not clear whether knowledge of the mitotic activity of the OSE will be informative since it is quite possible, as Dubeau (1999) has emphasized, that the OSE is not the cell of origin of ovarian cancers. Dubeau argues that ovarian carcinomas as well as adenomas are similar histologically to the tissue of the fallopian tube, endometrium and cervix, that is, they appear to have been derived from Mullerian tissue, and that the evidence for metaplasia of the OSE to produce such tumors is weak. Recent results from the study of ovaries from prophylactic oophorectomies in women with BRCA1 mutations strongly suggest, however, that the ovarian cancers associated with such mutations do arise in inclusion cysts (J Boyd, unpublished results presented at the American Association for Cancer Research 2004 Annual Meeting).
Although there may be dispute regarding the cell of origin of ovarian cancer, there is general agreement that ovarian cystadenomas and ovarian cancers have the same cell of origin. There is some relevant information concerning mitogenic effects available from in vitro studies of cell lines established from the two tumor types. Such studies have shown stimulator effects of estrogen and inhibitory effects of progesterone at high steroid levels similar to intraovarian levels in ovulatory cycles (Zhou et al., 2002) . These and other observations have given rise to a 'high-estrogen/low-progestin hypothesis' for the etiology of ovarian cancer.
Ages at menopause and menarche
Although an increased risk of ovarian cancer in association with late age at natural menopause has been reported in a few studies including our own , no association has been found in many studies (see Schildkraut et al. (2001) and references therein). Age at menarche has generally not been identified as a risk factor for ovarian cancer.
Why an effect of age at menopause is not consistently found is difficult to reconcile with the age-incidence curve for the disease and with both of the proposed etiological hypotheses. It may be that the early stages of ovarian cancer affect ovarian function and cause an early menopause. If this is so, then a more clear effect of age at menopause should be seen if one restricted attention to ovarian cancer cases diagnosed after the age of 65 years, say. Such analyses have not been carried out.
The lack of an effect of early menarche can be explained on the high-estrogen/low-progesterone hypothesis since early menarche is associated with a more rapid onset of regular (ovulating) cycles than a late menarche, so that the amount of exposure to estrogen unopposed by progesterone may not be much affected by age at menarche.
Parity
There is a greater reduction in risk with first birth than with subsequent births (Whittemore et al., 1992; Risch et al., 1994; Ness et al., 2000; Titus-Ernstoff et al., 2001; Riman et al., 2002a ; Tung et al., 2003) : an approximately 40% reduction in risk with first birth compared to approximately 10% with each subsequent birth. This is partly due to the inclusion in the nulliparous group of women who were infertile, and there is evidence that they are at especially high risk (Whittemore et al., 1992; Ness et al., 2002) . However, based on these results, one can show that excluding such women only reduces the first birth reduction to 30%, still much greater than is seen with subsequent births.
Further analysis of the parity effect combining data from four US population-based case-control studies showed a reduced risk with late age at first birth (Whittemore et al., 1992) . This issue has now been investigated in a number of studies. In our study ), we found a major effect of age at last birth; the later the age at last birth the lower the risk of ovarian cancer. Compared to a nulliparous woman, the overall risk of ovarian cancer in a woman with a last birth after the age of 35 years was reduced by 58%, with a reduction of 51% solely due to the last birth. A last birth before the age of 25 years was associated with only a 16% reduced risk of ovarian cancer; even after adjusting for numbers of births this only increased to 20%. Additional births (before the last) reduced risk further by some 10% per birth.
Our results were in close agreement with the results seen in the study of Whiteman et al. (2003) . Owing to the strong positive relationship, at least in US studies, between late age at first birth and late age at last birth, the result reported by Whittemore et al. (1992) is also likely to be supportive of a late age at last birth effect. Titus-Ernstoff et al. (2001) also observed a trend of increased protective effect with late age at last birth. This effect was, however, not seen in two other population-based case-control studies (Risch et al., 1994; Riman et al., 2002a) , and the effect must currently be considered as not firmly established. The problem may be the difficulty of distinguishing the effect of ages of first birth and last birth and parity when these factors are highly correlated. Joint analyses of all these studies should be able to settle this important issue.
OC use
OC use is consistently found to provide very significant protection against ovarian cancer (see Riman et al. (2002a) , Royar et al. (2002) and Pike et al. (2004) and references therein). The reduction in risk for 12-15 months of OC use is the same as that associated with term pregnancies before the last (assuming the validity of the model that proposes a significant effect of age at last birth) or births after the first (assuming no effect of age at last birth). Ovarian function is more completely suppressed during mid-to late pregnancy than is ever achieved with OC use, and the early part of pregnancy is associated with high progesterone production in the ovary. With OC use, during the 7 days per 28-day cycle that the OC is not taken, some follicle development occurs with an associated production of estrogen. However, these considerations do not help clearly distinguish between the incessant ovulation hypothesis and the high-estrogen/low-progestin hypothesis.
A recent reanalysis of the CASH Study (Schildkraut et al., 2002) suggested that OC formulations with a 'high-dose/ potency' progestin may be associated with a greater reduction in risk than those with a 'low-dose/ potency' progestin. We observed this effect in our recent study , but our results were not statistically significant, and Ness et al. (2000) did not observe such an effect. Further data are needed to adequately evaluate this issue. Rodriguez et al. (1998 Rodriguez et al. ( , 2002b have proposed, based on long-term studies in macaques of extended exposure to OCs or the individual components of OCs, that it is a direct action of the progestin component on the OSE that provides the protection from OCs against ovarian cancer, not the blocking of ovulation and/or follicle development. In these studies, the progestin component of OCs, given alone without the estrogen component, showed increased apoptosis of the OSE very similar to that seen with OCs. This most interesting study is, however, difficult to interpret, since the progestin component alone would also block ovulation and follicle development, so that one cannot distinguish a direct progestin effect from an effect of suppression of follicle development and ovulation. This could be studied using a GnRH analog to suppress ovulation. It will be important in future studies to also study inclusion cysts, as we discussed above.
Obesity
Obesity is associated with anovulation in the premenopausal period and relatively high estrogen levels in the postmenopausal period. On the incessant ovulation hypothesis, premenopausal obesity would, therefore, be expected to be associated with decreased risk, and this effect should carry over at least for a time into the postmenopausal period (Pike, 1987) . The incessant ovulation hypothesis makes no prediction about the effect of postmenopausal obesity.
On the high-estrogen/low-progestin hypothesis, one would predict that premenopausal obesity would increase risk, since, during the anovular cycles, follicular levels of estrogen would occur throughout the cycle without their effect being interfered with by progesterone. In the postmenopausal period, obesity would again be predicted to increase risk because of the higher estrogen levels. It is, however, impossible at the current time to predict what the magnitude of this postmenopausal effect would be, since we have no knowledge of the dose-effect relationship between estrogen levels in the blood and 'ovarian-cell' proliferation; as we noted above, the in vitro work on ovarian cell proliferation was all done with very high levels of estrogen similar to that achieved premenopausally within the ovary.
What is the epidemiological evidence on the effect of obesity? A systematic review found a consistent positive association between body size and ovarian cancer risk in 11 population-based case-control studies and five cohort studies. Since that review, results from two other population-based case-control studies (Kuper et al., 2002; Lubin et al., 2003) and five cohort studies (Fairfield et al., 2002; Lukanova et al., 2002; Rodriguez et al., 2002a; Engeland et al., 2003; Schouten et al., 2003) have been published. Although one of these studies (Lukanova et al., 2002) with a small number of ovarian cancer cases did not find such an effect, all the other studies did. The increase in risk between the upper and lower quartiles of body mass index (BMI) is around 30%. This analysis was essentially restricted to postmenopausal BMI, but a similar effect has been found with premenopausal obesity (Casagrande et al., 1979; Farrow et al., 1989; Tornberg and Carstensen, 1994; Purdie et al., 2001) . Thus, the evidence appears quite definite: increasing weight is associated with increasing risk. This observed association may, however, be misleading as regards etiology.
In a population-based ovarian cancer case-control study we recently completed , risk increased over four increasing BMI categories (o25, 25À, 30À and 35 þ kg/m 2 ) from 1.0 to 0.97 to 1.29 to 1.46, as was seen in the Purdie et al. (2001) review. However, the increasing trend was restricted to Localized disease, for which the risk increased from 1.0 to 1.42 to 2.66 to 3.43. There was only a very weak relationship between BMI and risk of Regional/Distant disease; the odds ratios over the same increasing BMI categories were 1.0, 0.89, 1.07 and 1.16. In this same study, we noted from review of pathology reports that many of the Localized disease cases (20% of the total cases) were diagnosed as a consequence of some other complaint, in many cases vaginal bleeding associated with an endometrial cancer primary or an abdominal mass associated with an abdominal nonovarian primary. (These cases were omitted in calculating the relationship of BMI to risk.) When one considers the reasons why a Localized disease case would be diagnosed, it is clear that increasing BMI could simply be associated with the reason for a medical work-up rather than with ovarian cancer itself. Further investigation of the etiological significance of BMI is needed.
Menopausal hormone therapy (HT)
The current epidemiological evidence obtained from cohort and population-based case-control studies with data on formulation and duration of use of menopausal HT suggests that unopposed menopausal ET increases ovarian cancer risk (Weiss et al., 1982; Cramer et al., 1983; Lee et al., 1986; Risch, 1996; Purdie et al., 1999; Rodriguez et al., 2001; Lacey et al., 2002; Riman et al., 2002b; Sit et al., 2002) . Our meta-analysis of ET use in these studies, together with the results of our own study that found a nonsignificant increase in risk, found a statistically highly significant increased risk of approximately 24% at 5 years of ET use. The estimated overall risk associated with EPT use was smaller, 13% at 5 years of EPT use, and was not statistically significant.
If BMI is related to ovarian cancer risk only incidentally through increasing BMI being related to increased contact with the medical system, then this would cast some doubt on the increased incidence seen with ET use since BMI is associated with increased postmenopausal estrogen levels and decreased sexhormone-binding globulin. One would therefore expect to see a clear association with BMI if the ET result was true.
Some of the observed risk seen with ET use may be a diagnostic bias since we found that the ET effect was much smaller in our study when we restricted attention to Regional/Distant disease. With Localized disease, we estimated the risk at 5 years of ET use as 1.51 and 1.22 for natural menopause and hysterectomized women respectively, while for Regional/Distant disease these risks were 1.11 and 1.10 respectively. A joint careful analysis of the published studies is again needed to help clarify this issue.
Other risk factors
Hysterectomy has been consistently found to be a protective factor. Although interpretation of this result in some studies is not always clear as women whose hysterectomy included oophorectomy may have been mistakenly included in the control group, the overall results strongly suggest that this effect is real . Tubal ligation has also been consistently found to be protective. Use of talc in the genital area has also consistently been found to increase risk. The underlying reasons for these effects are not understood.
Histology
The above results are generally seen with the different histological varieties of ovarian cancer, although there have been suggestions of some factors being more important for endometrioid tumors. This can, however, only be properly studied if one takes into account the strong relationship between histology and stage of disease. Data from the Los Angeles Cancer Surveillance Program, the National Cancer Institute's SEER registry for Los Angeles County, showed that the majority (approximately two-thirds) of ovarian cancer cases were histologically classified as serous, around 20% as endometrioid (including clear cell) and 10% as mucinous: for serous tumors, 12% were Localized; for endometrioid, 42%; and for mucinous, 55%. Further detailed analysis of the reasons why the Localized tumors came to be diagnosed, may be most informative.
Chemoprevention
What is the current situation regarding chemopreventive strategies against ovarian cancer? OC use remains an effective approach: in our data, and in recently published studies, the protective effect was seen to be very long term extending to women over the age of 60 years who had used OCs many years in the past.
If the finding of a major protective effect of a late birth can be confirmed, then we may be able to use this for a short-term chemoprevention strategy with a longterm preventive effect. To do this, we will need to understand the mechanism of the protective effect. We did not find late incomplete pregnancies or late OC use to provide such an effect, so we must look for the distinctive characteristics of a full-term pregnancy.
It is possible that the prolonged high levels of progesterone during a term pregnancy will be lethal to or 'terminally differentiate' a significant proportion of 'premalignant' ovarian cancer precursor cells. Detailed study of the ovaries, including OSE and inclusion cysts, of women immediately after delivery should be most informative. It would also be important to closely observe the fallopian tubes as microscopic ovarian cancers have been found outside the ovary and closely associated with the fallopian tubes in some studies looking for early lesions in women with BRCA1 mutations undergoing prophylactic oophorectomies (Piek et al., 2001 ). These observations, of course, are supportive of the ideas of Dubeau (1999) regarding the cell of origin of at least some 'ovarian cancers'. Such studies should also be undertaken in macaques or other lower primates as was done by Rodriguez et al. (1998 Rodriguez et al. ( , 2002b to study the effect of OCs. In vitro experiments on the effects of prolonged pregnancy levels of estrogen and progesterone on ovarian cystadenoma cells may also be informative.
Conclusion
Analysis of the age-specific incidence curves for three of the most important cancers of women, namely, breast, endometrium and ovary, shows that menopause has a large protective effect on each of them. If ovarian function continued till the age of 70 years, extrapolation of the premenopausal incidence curves suggests that the incidence rates of these tumors in old age would be increased fourfold for breast, fivefold for ovary and eightfold for endometrium. This protective effect of menopause remains the central clue to the etiology of these cancers, and hence to their chemoprevention.
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